Equity Overview
Price & Market Data
Price: $33.80
Daily Change: +$0.48 / 1.42%
Range: $32.03 - $33.80
Market Cap: $3,080,984,832
Volume: 637,117
Performance Metrics
1 Week: -5.20%
1 Month: 6.25%
3 Months: -6.21%
6 Months: -27.11%
1 Year: 234.5%
YTD: -24.92%
Company Details
Employees: 196
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.